Brief: Ribomic Enters License Agreement With Aju Pharma For Rbm-007 In Age-Related Macular Degeneration

Ribomic

17/03/2020 17:34

March 17 (Reuters) - Ribomic Inc  4591.T :
    * RIBOMIC ENTERS LICENSE AGREEMENT WITH AJU PHARMA FOR
RBM-007 IN
AGE-RELATED MACULAR DEGENERATION
    * RIBOMIC - UPON EXECUTION OF AGREEMENT, AJU WILL OBTAIN
EXCLUSIVE
LICENSE TO DEVELOP AND SELL PRODUCT CONTAINING RBM-007 IN
TERRITORY
    * RIBOMIC -  WILL RECEIVE AN UPFRONT PAYMENT OF US$1 MILLION
AND
IS ELIGIBLE FOR POTENTIAL DEVELOPMENT MILESTONE PAYMENTS OF UP
TO US$5 MILLION
    * RIBOMIC- WILL SUPPLY PRODUCT TO AJU AT PRODUCT SUPPLY
PRICES,
WHICH INCLUDES ROYALTIES, FOR AJU'S SALE OF PRODUCT IN TERRITORY
    * RIBOMIC - RBM-007 IS CURRENTLY BEING EVALUATED IN A PHASE
2
STUDY

Source text:  urn:newsml:reuters.com:*:nBw76qc2sa
Further company coverage:  4591.T 

 ((Reuters.Briefs@thomsonreuters.com;))